|
|
| | ARS-1323 Basic information |
| Product Name: | ARS-1323 | | Synonyms: | ARS1323;ARS 1323;ARS-1323;ARS-1323;CPD2015;2-Propen-1-one, 1-[4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-quinazolinyl]-1-piperazinyl]-;Inhibitor,Ras,ARS1323,ARS 1323,inhibit,ARS-1323 | | CAS: | 1698024-73-5 | | MF: | C21H17ClF2N4O2 | | MW: | 430.84 | | EINECS: | | | Product Categories: | | | Mol File: | 1698024-73-5.mol |  |
| | ARS-1323 Chemical Properties |
| Boiling point | 614.7±55.0 °C(Predicted) | | density | 1.434±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 125 mg/mL (290.13 mM) | | pka | 6.03±0.35(Predicted) |
| | ARS-1323 Usage And Synthesis |
| Uses | ARS-1620, is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics. | | Definition | ChEBI: ARS-1620 is a qinazoline derivative carrying chloro and fluoro substituents at positions 6 and 8 respectively, a 2-fluoro-6-hydroxyphenyl group at position 7, and a 4-(prop-2-enoyl)piperazin-1-yl group at position 4. A potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor, it inhibits the protein coding gene KRAS (Kirsten rat sarcoma virus) with high potency in cells and animals. It has a role as an inhibitor, an antiviral agent and an antineoplastic agent. |
| | ARS-1323 Preparation Products And Raw materials |
|